Press "Enter" to skip to content

Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics

FDA issues a new draft guidance on the application of the benefit-risk assessment framework for evaluating applications for opioids.

Original source: http://www.fda.gov/news-events/press-announcements/statement-fdas-benefit-risk-framework-evaluating-opioid-analgesics

Also Read:   FDA approves treatment for patients with rare bone marrow disorder